Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan
Rhea-AI Filing Summary
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in Mineralys Therapeutics, Inc. common stock. On March 12–13, 2026, he exercised stock options for a total of 14,057 shares of common stock at exercise prices of $1.08, $10.20, and $14.25 per share. He then sold 20,406 shares in open-market transactions at weighted-average prices between approximately $25.77 and $27.92, executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 76,140 shares of Mineralys Therapeutics common stock.
Positive
- None.
Negative
- None.
Insights
Routine exercise-and-sell by CMO under a pre-planned Rule 10b5-1 trading program.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom exercised stock options for 14,057 shares of common stock at strike prices of $1.08, $10.20, and $14.25. These are typical compensation-related derivative exercises converting options into shares.
He then sold 20,406 shares in open-market transactions at weighted-average prices ranging from about $25.77 to $27.92. Footnotes state that all trades were made pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating the timing was pre-arranged rather than opportunistic.
After the transactions, he directly owns 76,140 common shares, so the activity represents a partial adjustment rather than an exit. With no remaining derivative positions shown in the derivativeSummary, this filing reflects exercises of options and related sales under a structured liquidity plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 3,542 | $0.00 | -- |
| Exercise | Stock Option | 4,167 | $0.00 | -- |
| Exercise | Common Stock | 3,542 | $10.20 | $36K |
| Exercise | Common Stock | 4,167 | $14.25 | $59K |
| Sale | Common Stock | 10,726 | $25.9111 | $278K |
| Sale | Common Stock | 3,079 | $27.3675 | $84K |
| Sale | Common Stock | 253 | $27.82 | $7K |
| Exercise | Stock Option | 6,348 | $0.00 | -- |
| Exercise | Common Stock | 6,348 | $1.08 | $7K |
| Sale | Common Stock | 6,348 | $27.3705 | $174K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.92. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.772 to $27.720. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
